Azura Ophthalmics Ltd.

Pharmos Corporation

Regenera Pharma Ltd.

Painreform Ltd.

Other

Alcobra Ltd.

M.g. Therapeutics, Ltd.

US Government As Represented by the Secretary of the Army

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Adama Makhteshim, Ltd.

Coeruleus Ltd.

Spacepharma R&d Israel Ltd.

Shimon Amselem

Doron Friedman

Omer Rafaeli

Cary J Reich

Yair Alster

Kirsten Angela Macfarlane

K Angela Macfarlane

Zadik Hazan

Zakhar Nudelman

Michael Naveh

Yaron Ilan

Dalia Megiddo

Rina Yamin

Joseph Schwarz

Gur Megiddo

Yechezkel Barenholz

Haim Aviv

Zoltán Fülöp

Joseph Schwartz

George H Lowell

István Puskás

Guy Samburski

Lital Koren

Tamás Sohajda

Cary Reich

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said methods are performed by administering said composition comprising a selenium disulfide and an anhydrous semi-solid base. The stable anhydrous composition are substantially free of selenium disulfide agglomerates.

Selenium disulfide compositions for use in treating meibomian gland dysfunction

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

Compositions and methods for the treatment of meibomian gland dysfunction

The present invention relates pesticidal complexes, pesticidal delivery systems and compositions, as well as processes of preparation and uses thereof. The present invention also relates to the use of cyclodextrins for increasing biological activity and improving uptake, penetration, retention and/or bioavailability of agrochemicals such as pesticides.

Use of cyclodextrins as agrochemical delivery system

Disclosed is a method for crystallizing molecules having a molecular weight equal to or lower than about 500 Dalton in a gravity below about 0.01 g to about 0.000001 g as well as to crystalline molecules having a molecular weight equal to, or lower than, about 500 Dalton, prepared under microgravity conditions.

Drug crystallization under microgravity conditions

Described herein are compositions and methods for the increasing the quantity of lipids secreted from meibomian glands. Such compositions and methods are useful for the treatment of meibomian gland dysfunction and disorders resulting therefrom.

Agents for increasing meibomian gland lipid secretion

Compositions and formulations comprising polymeric myrcene. More particularly, the invention relates to compositions comprising an isolated fraction of polymeric myrcene in a hydrophobic carrier and formulations which maintain the biological activity of the active polymer.

Compositions of polymeric myrcene

Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion

Growing community of inventors

Rehovot, Israel

Shimon Amselem